SM
RNAZ icon

Sabby Management’s TransCode Therapeutics RNAZ Stock Holding History

Sabby Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,180
Closed -$113K – 63
2025
Q1 		$113K Buy
+8,180
New +$1.05M 0.33% 36
2024
Q2 		– Sell
-362
Closed -$229K – 56
2024
Q1 		$229K Buy
+362
New +$506K 0.13% 23
2023
Q4 		– Sell
-7
Closed -$126K – 81
2023
Q3 		$126K Buy
7
+2
+40% +$126K 0.09% 44
2023
Q2 		$433K Buy
+5
New +$977K 0.35% 32

Other funds holding RNAZ

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SC
SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sabby Management's RNAZ Position: Q2 2025 in Review

Sabby Management sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 8,180 shares — an estimated $113K sold.

Sabby Management first reported a position in RNAZ in Q2 2023 and held it in 4 quarters. The position peaked at $433K in Q2 2023. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

  • Sabby Management reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sabby Management sold 8,180 TransCode Therapeutics shares in Q2 2025, an estimated $113K.
  • Sabby Management first reported a position in TransCode Therapeutics in Q2 2023 and held it in 4 quarters.
  • Sabby Management's TransCode Therapeutics position peaked at $433K in Q2 2023.
  • 9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Sabby Management's 13F filing for Q2 2025, filed 14 Aug 2025.